FDA approves two next-gen miniaturized, leadless pacemakers with extended battery life
Medtronic announced it received FDA approval for two of its next-generation miniaturized, leadless pacemakers that are less than one-tenth the size of traditional pacemakers.
The median projected battery life of the two devices is nearly 16 years (Micra AV2) and 17 years (Micra VR2) — approximately 40% more compared with previous generations, according to a press release.
One of the next generation pacemakers (Micra AV2) includes algorithms to automatically program atrioventricular synchrony and a higher available tracking capability for the faster heart rates of active patients, according to the release.
“Improved [atrioventricular] synchrony — requiring less in-office reprogramming thanks to algorithm optimization — and longer battery life are major wins for patients,” Camille G. Frazier-Mills, MD, MHS, electrophysiologist at Duke University Health System, said in the release. “I’m excited to offer my patients the new Micra devices. This best-in-class technology transforms the patient experience by eliminating pocket-related complications, and now reduces the chance that patients will need their device changed in the future.”
Collapse
Read more about